Chromadex Corp (OQ:CDXC)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 10900 Wilshire Blvd, Suite 600
LOS ANGELES CA 90024
Tel: N/A
Website: https://chromadex.com/default.aspx
IR: See website
<
Key People
Robert N. Fried
Chief Executive Officer, Director 		Brianna Gerber
Chief Financial Officer 		 
Business Overview
Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
Financial Overview
For the fiscal year ended 31 December 2023, Chromadex Corp revenues increased 16% to $83.6M. Net loss decreased 70% to $4.9M. Revenues reflect Consumer Products Segments increase of 16% to $69.5M, Ingredients Segments increase of 27% to $11.1M. Lower net loss reflects Consumer Products Segments income increase from $6.5M to $14.5M, Corporate and other segment loss decrease of 12% to $25M, Ingredients Segments income increase of 50% to $5.4M.
Employees: 106 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $258.27M as of Dec 31, 2023
Annual revenue (TTM): $83.57M as of Dec 31, 2023
EBITDA (TTM): -$4.54M as of Dec 31, 2023
Net annual income (TTM): -$4.94M as of Dec 31, 2023
Free cash flow (TTM): $6.97M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 75,309,118 as of Mar 4, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More